SML2682

RIPGBM

≥98% (HPLC)

• Synonym(e): N-(3-(Benzylamino)-1,4-dioxo-1,4-dihydronaphthalen-2-yl)-N-(4-fluorobenzyl)acetamide, N-[1,4-Dihydro-1,4-dioxo-3-[(phenylmethyl)amino]-2-naphthalenyl]-N-[(4-fluorophenyl)methyl]acetamide, cRIPGBM precursor
• Empirische Formel (Hill-System): C₂₆H₂₁FN₂O₃
• CAS-Nummer: 355406-76-7
• Molekulargewicht: 428.45
• UNSPSC-Code: 12352200
• NACRES: NA.77

Eigenschaften

• Assay: ≥98% (HPLC)
• Form: powder
• Farbe: faint brown to very dark brown-red
• Löslichkeit: DMSO: 2 mg/mL, clear
• Lagertemp.: 2-8°C
• SMILES String: O=C1C(N(CC2=CC=C(F)C=C2)C(C)=O)=C(NCC3=CC=CC=C3)C(C4=C1C=CC=C4)=O
• InChI: 1S/C26H21FN2O3/c1-17(30)29(16-19-11-13-20(27)14-12-19)24-23(28-15-18-7-3-2-4-8-18)25(31)21-9-5-6-10-22(21)26(24)32/h2-14,28H,15-16H2,1H3
• InChIKey: COATXBHZYVUJQP-UHFFFAOYSA-N

Beschreibung

Biochem./physiol. Wirkung

Orally active, brain-penetrant, GBM CSCs-selective apoptosis inducer with efficacy in a murine orthotopic xenograft model of glioblastoma multiforme in vivo.

RIPGBM is a brain-penetrant, orally available, glioblastoma multiforme (GBM) cancer stem cells (CSCs)-selective apoptosis inducer (GBM-1/-5/-39 EC50 = 220/290/890 nM; human neural progenitor cells (NPCs)/astrocytes/lung fibroblasts EC50 = 1.7/2.8/3.5 μM) with in vivo efficacy against intracranial human GBM orthotopic xenograft tumor growth in mice (50 mg/kg bid. po.). RIPGBM undergoes a cell type-selective metabolic redox conversion to preferentially form in GBM CSCs the derivative cRIPGBM that binds receptor-interacting protein kinase 2 (RIPK2, RIP2) and promotes the formation of a proapoptotic RIPK2/caspase-1 complex.

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable